From HandWiki - Reading time: 6 min
Fazamorexant (INN; developmental code name YZJ-1139) is an orexin receptor antagonist which is under development for the treatment of insomnia.[1][2][3][4] It is taken by mouth.[1]
The drug acts as a dual orexin receptor antagonist (DORA), or as an antagonist of both the orexin OX1 and OX2 receptors.[3][4] Its time to peak levels is 0.6 to 1.3 hours and its elimination half-life is 1.9 to 3.7 hours.[5]
Fazamorexant is under development by Jiangsu Yangtze River Pharmaceutical Group and/or Shanghai Haiyan Pharmaceutical Technology in China.[1][2][3] As of September 2022, it is in phase 3 clinical trials for insomnia.[1][2][4] Relatively little public information is available on fazamorexant.[3] This was such that it had to be excluded from a 2020 literature review of orexin receptor antagonists for insomnia.[3]